Chapter 6 │ Page 216 54. Clemen, R., et al. Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells. Cancers, 2020. 12, DOI: 10.3390/cancers12123575. 55. Beshr, M.S., et al., PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A MetaAnalysis. Clinical Oncology, 2024. 36(12): p. 797-808. 56. Knight, A., L. Karapetyan, and J.M. Kirkwood, Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel), 2023. 15(4). 57. Shields, M.D., J.A. Marin-Acevedo, and B. Pellini, Immunotherapy for Advanced Non– Small Cell Lung Cancer: A Decade of Progress. American Society of Clinical Oncology Educational Book, 2021(41): p. e105-e127. 58. Zhang, L., et al., Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis. Technology in Cancer Research & Treatment, 2024. 23: p. 15330338241273286. 59. Li, L., et al., Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel), 2023. 15(1). 60. Merck & Co., Inc. Selected indications for KEYTRUDA® (pembrolizumab). Rahway (NJ): Merck & Co., Inc.; 2025. Available: https://www.keytrudahcp. com/approvedindications/. 61. Patruni, S., et al., Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review. JCO Oncol Pract, 2023. 19(3): p. 107-115. 62. National Cancer Institute. Clinical trials using pembrolizumab. Bethesda (MD): NCI; 2025. Available: https://www.cancer.gov/about-cancer /treatment/clinicaltrials/search/results?swKeyword=pembrolizumab. 63. European Clinical Trials Register. Clinical trials for ipilimumab. 2025. Available: https://www.clinicaltrialsregister.eu/ctr-search/search?query= ipilimumab 64. Shaverdashvili, K., et al., A phase II clinical trial evaluating the safety and e icacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. eClinicalMedicine, 2023. 66. 65. Lu, C. and Y. Tan, Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Molecular Therapy: Oncology, 2024. 32(1): p. 200773. 66. Rufo, N., A.D. Garg, and P. Agostinis, The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy. Trends Cancer, 2017. 3(9): p. 643-658. 67. Bi, K., et al., Identification of known drugs targeting the endoplasmic reticulum stress response. Anal Bioanal Chem, 2015. 407(18): p. 5343-51. 68. Zhang, W., et al., Endoplasmic reticulum stress—a key guardian in cancer. Cell Death Discovery, 2024. 10(1): p. 343. 69. Mahameed, M., et al., Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nature Communications, 2020. 11(1): p. 1304.
RkJQdWJsaXNoZXIy MTk4NDMw